Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Lineage Cell Therapeutics Company

LCTX
US53566P1093
A2PP89

Price

0.86
Today +/-
+0.01
Today %
+1.21 %
P

Lineage Cell Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Lineage Cell Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Lineage Cell Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Lineage Cell Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Lineage Cell Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Lineage Cell Therapeutics Stock Price History

DateLineage Cell Therapeutics Price
10/11/20240.86 undefined
10/10/20240.85 undefined
10/9/20240.88 undefined
10/8/20240.87 undefined
10/7/20240.88 undefined
10/4/20240.91 undefined
10/3/20240.90 undefined
10/2/20240.92 undefined
10/1/20240.90 undefined
9/30/20240.91 undefined
9/27/20240.92 undefined
9/26/20240.86 undefined
9/25/20240.89 undefined
9/24/20240.89 undefined
9/23/20240.94 undefined
9/20/20240.94 undefined
9/19/20240.91 undefined
9/18/20240.88 undefined
9/17/20240.91 undefined
9/16/20240.93 undefined
9/13/20240.91 undefined

Lineage Cell Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Lineage Cell Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Lineage Cell Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Lineage Cell Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Lineage Cell Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Lineage Cell Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Lineage Cell Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Lineage Cell Therapeutics’s growth potential.

Lineage Cell Therapeutics Revenue, EBIT and net profit per share

DateLineage Cell Therapeutics RevenueLineage Cell Therapeutics EBITLineage Cell Therapeutics Net Income
2029e227.82 M undefined0 undefined-19.26 M undefined
2028e155.13 M undefined82.65 M undefined-25.04 M undefined
2027e69.39 M undefined11.63 M undefined-26.97 M undefined
2026e25.72 M undefined-29.86 M undefined-32.74 M undefined
2025e11.91 M undefined-36.98 M undefined-28.89 M undefined
2024e5.32 M undefined-24.34 M undefined-29.28 M undefined
20238.95 M undefined-24.73 M undefined-21.49 M undefined
202214.7 M undefined-22.52 M undefined-26.27 M undefined
20214.34 M undefined-49.21 M undefined-43.02 M undefined
20201.83 M undefined-26.45 M undefined-20.65 M undefined
20193.52 M undefined-38.88 M undefined-11.71 M undefined
20184.99 M undefined-40.99 M undefined-45.99 M undefined
20173.46 M undefined-40.65 M undefined-19.98 M undefined
20165.92 M undefined-58.97 M undefined33.57 M undefined
20157.04 M undefined-65.81 M undefined-47.41 M undefined
20145.24 M undefined-50.68 M undefined-36.5 M undefined
20134.43 M undefined-38.53 M undefined-43.88 M undefined
20123.92 M undefined-25 M undefined-21.43 M undefined
20114.43 M undefined-18.69 M undefined-16.52 M undefined
20103.71 M undefined-9.85 M undefined-11.18 M undefined
20091.93 M undefined-3.52 M undefined-5.14 M undefined
20081.5 M undefined-2.82 M undefined-3.78 M undefined
20071.05 M undefined-1.22 M undefined-1.44 M undefined
20061.16 M undefined-1.75 M undefined-1.87 M undefined
2005900,000 undefined-2.02 M undefined-2.08 M undefined
2004690,000 undefined-1.92 M undefined-3.09 M undefined

Lineage Cell Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000001100000011113434575343141485112569155227
--------------------200.0033.33-25.0033.3325.0040.00-28.57-40.0033.33-25.00-66.67300.00250.00-42.86-37.50120.00127.27176.00124.6446.45
--------------------100.00100.00100.0075.0080.0071.43100.00100.00100.00100.00100.0050.0092.86100.00------
00000000000000000000343345534312138000000
000-1-1-2-2-3-3-5-5-3-2-1-1-2-1-1-2-3-9-18-25-38-50-65-58-40-40-38-26-49-22-24-24-36-2911820
---------300.00-500.00-------100.00-100.00-200.00-300.00-300.00-450.00-833.33-950.00-1,000.00-928.57-1,160.00-1,333.33-1,000.00-1,266.67-2,600.00-1,225.00-157.14-300.00-480.00-327.27-116.0015.9452.90-
000-1-1-2-1-3-3-5-4-3-2-1-3-2-1-1-3-5-11-16-21-43-36-4733-19-45-11-20-43-26-21-29-28-32-26-25-19
-----100.00-50.00200.00-66.67-20.00-25.00-33.33-50.00200.00-33.33-50.00-200.0066.67120.0045.4531.25104.76-16.2830.56-170.21-157.58136.84-75.5681.82115.00-39.53-19.2338.10-3.4514.29-18.75-3.85-24.00
3.253.253.95.246.147.97.838.889.8310.6911.0411.5612.3714.2617.4517.922.5422.8523.7529.340.2747.0549.2154.2366.4779.7199.55114.48126.9145.53150.04164.5169.79172.66000000
----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Lineage Cell Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Lineage Cell Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (k)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                               
3.45.73.42.47.84.12.45.31.31.71.30.71.41.80.60012.233.322.24.35.529.54322.738.230.730.741.658.457.935.49
0000000000000000000.10.41.51.10.91.30.50.10.90050.80.30.75
0000000000000000000.60.6000.50.30.72.92.823.90000
00020010000000000000000100100200300000000000
0.10.10.10.20.30.20.20.10.10.10.10.30.10.10.10.10.10.11.51.71.31.21.22.61.81.41.92.92.42.41.82.2
3.55.83.52.88.24.32.65.41.41.81.411.51.90.70.10.112.335.5257.2832.447.225.742.636.357.544111.66038.44
0.10.10.10.10.10.20.20.30.20.20.1000000.10.10.71.31.332.97.55.55.55.88.25.64.95.74.77
000000000000000000000004.7100117.233.700000
0000000000000000000000000022.100000
00000000000000000015.418.620.546.238.833.610.26.93.148.24746.846.746.56
00000000000000000000000000010.710.710.710.710.67
000000.10.10000000000.80.91.60.90.70.60.81.61.110.50.90.60.60.60.58
0.10.10.10.10.10.30.30.30.20.20.1000000.9117.720.822.549.842.547.4116.8130.665.26863.96363.762.58
3.65.93.62.98.34.62.95.71.621.511.51.90.70.1113.353.245.829.757.874.994.6142.5173.2101.5125.5107.9174.6123.7101.02
                                                               
5.59.59.310.817.618.61927.228.430.632.432.938.740.340.440.743.259.7101.1115.1119.8203.5238.4274.3317.9378.5354.3387.1393.9434.5440.3451.34
1001001001001001001001001001001001001001001001001001001001001001000000000000
-2.2-3.7-6.1-8.1-11.2-14.6-16.7-22.2-27.1-30.8-33.6-35.4-38.5-40.5-42.4-43.8-47.6-52.8-64-80.5-101.9-145.8-182.2-229.2-196.3-216.3-261.9-273.4-294.1-337.1-363.4-384.86
0000000000000000000.9-0.1-0.10.10.2-0.2-0.70.51.4-0.7-3.7-5.2-3.6-3.07
00000000000000000000000000000000
3.45.93.32.86.54.12.45.11.4-0.1-1.1-2.40.3-0.1-1.9-3-4.3738.134.617.957.956.444.9120.9162.793.811396.192.273.363.42
000.30.10.20.20.20.60.40.20.40.40.30.60.40.51.20.511.11.23.92.32.81.60.92.42.42.63.52.42.05
0000000000.10.100.1000000.40.60.50.64.16.25.34.94.344.4257.15.05
00001.10.40.2000000.10.10.20.30.30.61.11.42.72.50.63.410.90.100.218.59.410.81
0000000000000000.71.900000000.80000.5000
000000000002.7000000000000.10.10.20.100000.05
000.30.11.30.60.40.60.40.30.53.10.50.70.61.53.41.12.53.14.47712.58.86.96.96.47.74718.917.96
0000000001.72.2000000000000.552.81.220.1000.10.09
0000000000000000000008.34.500003.32.12.12.10.27
0.10.10.100.40000000.40.71.41.91.821.21.41.21.10.20.10.80.40.90.64.3334.430.620.67
0.10.10.100.400001.72.20.40.71.41.91.821.21.41.21.18.55.15.83.22.12.67.75.136.532.821.04
0.10.10.40.11.70.60.40.60.422.73.51.22.12.53.35.42.33.94.35.515.512.118.31299.514.112.883.551.739
3.563.72.98.24.72.85.71.81.91.61.11.520.60.31.19.34238.923.473.468.563.2132.9171.7103.3127.1108.9175.7125102.42
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Lineage Cell Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Lineage Cell Therapeutics's financial health and stability.

Assets

Lineage Cell Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Lineage Cell Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Lineage Cell Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Lineage Cell Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1991199219931994199519961997199819981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00-1-1-2-1-3-3-2-5-4-3-2-1-3-2-1-1-3-5-11-16-21-43-36-4633-19-45-11-20-43-26-21
0000000000000000000002238643332000
00000000000000000000000-3-7-40000000-1
00000010000000000010000203020-112118-10
000000000000001000013201418-71-1216-1701129
0000000000000000000000000000000000
0000000000000000000000000000000000
00-1,000-1,000-2,000-2,000-1,000-4,000-2,000-4,000-4,000-3,000-2,0000-1,000-1,000-1,000-1,000-1,000-4,000-7,000-13,000-19,000-29,000-38,000-44,000-42,000-30,000-30,000-31,000-19,000-23,0001,000-28,000
00000000000000000000000-20-5-2-1-300000
00-1-340000000000000003-10-3-1-7-10-101116139-4646
00-1-35000000000000000300-10-2-8-815171310-4547
0000000000000000000000000000000000
00000000000300-100022000000100025000
660401600700204100014253135636133585053816
5503016007031021002162531346364325550293616
-1-1000000000000000000000003-1-3000-100
0000000000000000000000000000000000
44-302-15-3-12-300000-1001221-11-1712312-2014-13-142323-4424
-0.63-0.63-1.3-1.6-2.09-2.15-1.32-4.6-2.07-4.56-4.89-3.22-2.13-0.66-1.54-1.41-1.27-1.25-1.71-4.32-7.95-14.55-20.08-31.79-39.55-49.87-44.86-31.85-34.17-32.39-19.81-23.910.65-29.24
0000000000000000000000000000000000

Lineage Cell Therapeutics stock margins

The Lineage Cell Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lineage Cell Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lineage Cell Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Lineage Cell Therapeutics's sales revenue. A higher gross margin percentage indicates that the Lineage Cell Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Lineage Cell Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Lineage Cell Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Lineage Cell Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Lineage Cell Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Lineage Cell Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Lineage Cell Therapeutics Margin History

Lineage Cell Therapeutics Gross marginLineage Cell Therapeutics Profit marginLineage Cell Therapeutics EBIT marginLineage Cell Therapeutics Profit margin
2029e92.5 %0 %-8.45 %
2028e92.5 %53.28 %-16.14 %
2027e92.5 %16.76 %-38.86 %
2026e92.5 %-116.11 %-127.33 %
2025e92.5 %-310.54 %-242.63 %
2024e92.5 %-457.25 %-549.92 %
202392.5 %-276.5 %-240.2 %
202295.1 %-153.2 %-178.71 %
202167.28 %-1,133.87 %-991.24 %
202078.69 %-1,445.36 %-1,128.42 %
201988.07 %-1,104.55 %-332.67 %
201893.99 %-821.44 %-921.64 %
201795.09 %-1,174.86 %-577.46 %
201694.09 %-996.11 %567.06 %
201584.23 %-934.8 %-673.44 %
201484.16 %-967.18 %-696.56 %
201382.17 %-869.75 %-990.52 %
201288.78 %-637.76 %-546.68 %
201198.19 %-421.9 %-372.91 %
201099.19 %-265.5 %-301.35 %
200992.5 %-182.38 %-266.32 %
200892.5 %-188 %-252 %
200792.5 %-116.19 %-137.14 %
200692.5 %-150.86 %-161.21 %
200592.5 %-224.44 %-231.11 %
200492.5 %-278.26 %-447.83 %

Lineage Cell Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Lineage Cell Therapeutics earnings per share therefore indicates how much revenue Lineage Cell Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lineage Cell Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lineage Cell Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lineage Cell Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lineage Cell Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lineage Cell Therapeutics Revenue, EBIT and net profit per share

DateLineage Cell Therapeutics Sales per ShareLineage Cell Therapeutics EBIT per shareLineage Cell Therapeutics Earnings per Share
2029e1.21 undefined0 undefined-0.1 undefined
2028e0.82 undefined0 undefined-0.13 undefined
2027e0.37 undefined0 undefined-0.14 undefined
2026e0.14 undefined0 undefined-0.17 undefined
2025e0.06 undefined0 undefined-0.15 undefined
2024e0.03 undefined0 undefined-0.16 undefined
20230.05 undefined-0.14 undefined-0.12 undefined
20220.09 undefined-0.13 undefined-0.15 undefined
20210.03 undefined-0.3 undefined-0.26 undefined
20200.01 undefined-0.18 undefined-0.14 undefined
20190.02 undefined-0.27 undefined-0.08 undefined
20180.04 undefined-0.32 undefined-0.36 undefined
20170.03 undefined-0.36 undefined-0.17 undefined
20160.06 undefined-0.59 undefined0.34 undefined
20150.09 undefined-0.83 undefined-0.59 undefined
20140.08 undefined-0.76 undefined-0.55 undefined
20130.08 undefined-0.71 undefined-0.81 undefined
20120.08 undefined-0.51 undefined-0.44 undefined
20110.09 undefined-0.4 undefined-0.35 undefined
20100.09 undefined-0.24 undefined-0.28 undefined
20090.07 undefined-0.12 undefined-0.18 undefined
20080.06 undefined-0.12 undefined-0.16 undefined
20070.05 undefined-0.05 undefined-0.06 undefined
20060.05 undefined-0.08 undefined-0.08 undefined
20050.05 undefined-0.11 undefined-0.12 undefined
20040.04 undefined-0.11 undefined-0.18 undefined

Lineage Cell Therapeutics business model

Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.com.

Lineage Cell Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Lineage Cell Therapeutics Revenue by Segment

Segmente2021202020192018
Grant Revenue---3.57 M USD
Royalties From Product Sales and License Fees-773,000 USD-392,000 USD
Grant-1.05 M USD--
Subscription and Advertisement Revenues---691,000 USD
Sale of Research Products and Services---333,000 USD
Grant Revenue--2.04 M USD-
Royalties From Product Sales and License Fees--1.22 M USD-
Sale of Research Products and Services--257,000 USD-
Royalties2.78 M USD---
Collaboration Revenues1.12 M USD---
Grant Revenues445,000 USD---

Lineage Cell Therapeutics Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Lineage Cell Therapeutics Revenue by Segment

DateAsiaForeignRevenue from area of domesticUnited States
2021-446,000 USD-3.9 M USD
2020-666,000 USD-1.16 M USD
2019-1.42 M USD-2.09 M USD
2018-3.18 M USD-1.8 M USD
20151.06 M USD-5.98 M USD-
20141.66 M USD-3.59 M USD-

Lineage Cell Therapeutics SWOT Analysis

Strengths

Lineage Cell Therapeutics Inc possesses several key strengths that contribute to its competitive advantage:

  • Strong Research and Development Capabilities: Lineage Cell Therapeutics Inc boasts a robust research and development team that consistently generates innovative scientific breakthroughs.
  • Patented Technologies and Intellectual Property: The company owns a significant portfolio of patents and intellectual property rights, providing a strong foundation for future growth and product development.
  • Established Partnerships: Lineage Cell Therapeutics Inc has established strategic partnerships with leading pharmaceutical companies, facilitating access to additional resources and expertise.
  • Well-regarded Management Team: The company is led by a talented and experienced management team with a proven track record in the biotechnology industry.

Weaknesses

Despite its strengths, Lineage Cell Therapeutics Inc faces several weaknesses that could impede its progress:

  • Limited Financial Resources: The company has struggled to secure adequate funding to support its ambitious research and development efforts, potentially hindering future expansion.
  • Narrow Product Portfolio: Lineage Cell Therapeutics Inc currently relies heavily on a limited number of product candidates, making it vulnerable to market shifts and competitive pressures.
  • Regulatory Challenges: Developing and commercializing advanced cell-based therapies requires navigating complex regulatory pathways, increasing the risk of delays and compliance issues.
  • Reliance on Unproven Technologies: The success of Lineage Cell Therapeutics Inc largely depends on the viability and market acceptance of its innovative cell therapy technologies, which are still in early stages of development.

Opportunities

Several opportunities exist for Lineage Cell Therapeutics Inc to capitalize on:

  • Expanding Market Demand: The growing demand for novel cell-based therapies in the healthcare industry presents significant growth opportunities for Lineage Cell Therapeutics Inc.
  • Emerging Markets: The company can explore expansion into emerging markets, where there may be a greater need for affordable and accessible cell therapies.
  • Strategic Collaborations: Lineage Cell Therapeutics Inc can further strengthen its position through collaborations with academic institutions, research organizations, and industry partners.
  • Technological Advancements: Rapid advancements in biotechnology offer opportunities for Lineage Cell Therapeutics Inc to leverage new technologies and enhance its product offerings.

Threats

Lineage Cell Therapeutics Inc should be mindful of the following threats that could impact its operations:

  • Intense Competition: The biotechnology industry is highly competitive, and Lineage Cell Therapeutics Inc faces competition from both established players and emerging startups.
  • Regulatory and Legal Challenges: Compliance with evolving regulations, potential litigation, and intellectual property disputes pose significant threats to Lineage Cell Therapeutics Inc's operations and market access.
  • Market Volatility: The market for cell-based therapies can be volatile, influenced by factors such as public perception, regulatory changes, and economic conditions.
  • Uncertain Commercialization Success: The successful commercialization of Lineage Cell Therapeutics Inc's product candidates is uncertain, as it depends on the completion of clinical trials, regulatory approvals, and market acceptance.

Lineage Cell Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Lineage Cell Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Lineage Cell Therapeutics shares outstanding

The number of shares was Lineage Cell Therapeutics in 2023 — This indicates how many shares 172.663 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lineage Cell Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lineage Cell Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lineage Cell Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lineage Cell Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lineage Cell Therapeutics stock splits

In Lineage Cell Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Lineage Cell Therapeutics.

Lineage Cell Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.05 -0.03  (36.03 %)2024 Q2
3/31/2024-0.04 -0.04  (-2.3 %)2024 Q1
12/31/2023-0.04 -0.03  (31.35 %)2023 Q4
9/30/2023-0.04 -0.04  (8.47 %)2023 Q3
6/30/2023-0.05 -0.03  (33.63 %)2023 Q2
3/31/2023-0.04 -0.03  (23.27 %)2023 Q1
12/31/2022-0.04 -0.03  (20.84 %)2022 Q4
9/30/2022-0.04 -0.04  (-12.04 %)2022 Q3
6/30/2022-0.04 -0.04  (8.47 %)2022 Q2
3/31/2022-0.03 -0.04  (-15.27 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Lineage Cell Therapeutics stock

Eulerpool World ESG Rating (EESG©)

53/ 100

🌱 Environment

60

👫 Social

42

🏛️ Governance

58

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lineage Cell Therapeutics shareholders

%
Name
Stocks
Change
Date
4.44010 % The Vanguard Group, Inc.8,384,68772,35512/31/2023
4.20759 % BlackRock Institutional Trust Company, N.A.7,945,620-754,20812/31/2023
3.62701 % Kingsley (Alfred D)6,849,24207/20/2023
22.06432 % Broadwood Capital, Inc.41,666,2556,730,7702/6/2024
2.63169 % Defender Capital LLC4,969,675-214,83512/31/2023
1.55466 % Geode Capital Management, L.L.C.2,935,811168,87412/31/2023
1.12880 % Raffles Capital Management, LLC2,131,621543,88212/31/2023
1.11026 % State Street Global Advisors (US)2,096,60973,76312/31/2023
0.98065 % Prescott General Partners LLC1,851,851012/31/2023
0.58872 % Northern Trust Investments, Inc.1,111,74812,46312/31/2023
1
2
3
4
5
...
10

Lineage Cell Therapeutics Executives and Management Board

Mr. Brian Culley51
Lineage Cell Therapeutics Chief Executive Officer, Director (since 2018)
Compensation 2.37 M
Mr. George Samuel42
Lineage Cell Therapeutics General Counsel, Corporate Secretary
Compensation 1.2 M
Ms. Jill Howe47
Lineage Cell Therapeutics Chief Financial Officer
Compensation 1.06 M
Mr. Alfred Kingsley80
Lineage Cell Therapeutics Non-Executive Independent Chairman of the Board
Compensation 304,750
Ms. Deborah Andrews65
Lineage Cell Therapeutics Independent Director
Compensation 154,000
1
2
3

Most common questions regarding Lineage Cell Therapeutics

What values and corporate philosophy does Lineage Cell Therapeutics represent?

Lineage Cell Therapeutics Inc represents values of innovation, dedication, and excellence in the field of cell therapy. The company's corporate philosophy revolves around utilizing the potential of stem cells to address unmet medical needs and improve patients' lives. With a focus on research and development, Lineage Cell Therapeutics Inc aims to deliver groundbreaking therapies that can revolutionize the treatment of age-related macular degeneration and other degenerative diseases. By harnessing the power of regenerative medicine, the company strives to offer hope and a better quality of life for patients worldwide.

In which countries and regions is Lineage Cell Therapeutics primarily present?

Lineage Cell Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Lineage Cell Therapeutics achieved?

Lineage Cell Therapeutics Inc, a leading biotechnology company, has achieved significant milestones in its journey. The company has made breakthrough advancements in the field of cell therapy, focusing on regenerative medicine and developing innovative treatments for degenerative diseases. Lineage Cell Therapeutics has successfully completed multiple clinical trials, demonstrating the safety and efficacy of its promising cell-based therapies. Additionally, the company has gained regulatory approvals and collaborated with renowned medical institutions to further its research and development efforts. With a dedicated team of experts and a commitment to improving patients' lives, Lineage Cell Therapeutics continues to make strides in the field of regenerative medicine.

What is the history and background of the company Lineage Cell Therapeutics?

Lineage Cell Therapeutics Inc, formerly known as BioTime Inc, is a clinical-stage biotechnology company focused on developing novel cell therapies for various diseases. With a rich history dating back to 1992, the company has been at the forefront of regenerative medicine research. Lineage Cell Therapeutics is dedicated to using its proprietary cell-based technologies to treat degenerative disorders and diseases. The company's extensive research expertise and collaborations have contributed to groundbreaking advancements in stem cell therapy. By leveraging its broad portfolio of cell lines, including pluripotent and progenitor cells, Lineage Cell Therapeutics aims to revolutionize the field of regenerative medicine and improve patient outcomes.

Who are the main competitors of Lineage Cell Therapeutics in the market?

The main competitors of Lineage Cell Therapeutics Inc in the market are reputable companies such as Fate Therapeutics Inc, bluebird bio Inc, and Celularity Inc.

In which industries is Lineage Cell Therapeutics primarily active?

Lineage Cell Therapeutics Inc is primarily active in the biotechnology and regenerative medicine industries.

What is the business model of Lineage Cell Therapeutics?

Lineage Cell Therapeutics Inc is a biotechnology company focused on developing innovative cell therapies for various medical conditions. Their business model revolves around utilizing their proprietary cell-based technology platform to create therapeutic products that address unmet medical needs. By harnessing the potential of pluripotent stem cells, Lineage aims to develop and commercialize novel therapies that can restore or replace damaged or dysfunctional cells in the body. This approach has the potential to revolutionize the treatment of diseases such as Parkinson's, spinal cord injury, macular degeneration, and more. Through strategic collaborations and partnerships, Lineage Cell Therapeutics Inc aims to advance their pipeline of cell therapy candidates and bring transformative treatments to patients in need.

What is the P/E ratio of Lineage Cell Therapeutics 2024?

The Lineage Cell Therapeutics P/E ratio is -5.04.

What is the P/S ratio of Lineage Cell Therapeutics 2024?

The Lineage Cell Therapeutics P/S ratio is 27.74.

What is the Quality Investing of Lineage Cell Therapeutics?

The Quality Investing for Lineage Cell Therapeutics is 4/10.

What is the revenue of Lineage Cell Therapeutics 2024?

The expected Lineage Cell Therapeutics revenue is 5.32 M USD.

How high is the profit of Lineage Cell Therapeutics 2024?

The expected Lineage Cell Therapeutics profit is -29.28 M USD.

What is the business model of Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a US-based company specializing in the development of cell therapies for the treatment of various diseases. The company's business model is based on the production and marketing of cell therapies derived from human embryonic stem cells. The company has various divisions, including neurology, ophthalmology, immunology, and oncology. In neuroscience, the company focuses on the therapy of spinal cord injuries, strokes, Alzheimer's disease, and other neurodegenerative diseases. In ophthalmology, the company focuses on the treatment of retinal diseases such as age-related macular degeneration and diabetic retinopathy. In immunology, Lineage Cell Therapeutics focuses on the treatment of autoimmune diseases such as type 1 diabetes and multiple sclerosis. In oncology, the company focuses on the development of cancer immunotherapies. The flagship product of Lineage Cell Therapeutics is OpRegen, a cell therapy for the treatment of retinal diseases. OpRegen is a product derived from pluripotent stem cells. It is currently in clinical trials, and the company hopes to bring it to market in the near future. Another product of Lineage Cell Therapeutics is OPC1, a cell therapy for the treatment of spinal cord injuries. OPC1 utilizes human embryonic stem cells differentiated into oligodendrocytes to repair damaged nerve fibers in the spinal cord. The product is currently in phase 1/2 studies. Lineage Cell Therapeutics is also working on the development of cancer immunotherapies based on the use of genetically modified T cells that can recognize and attack cancer cells. These therapies aim to provide more effective and targeted treatment for cancer. The company's business model involves the development and marketing of cell therapies derived from human embryonic stem cells. Lineage Cell Therapeutics works closely with academic institutions and research partners to develop new treatments and expand therapy options for patients. To further expand its business model, the company has undertaken various strategic partnerships and acquisitions. In 2018, Lineage Cell Therapeutics acquired Asterias Biotherapeutics to strengthen its position in the treatment of spinal cord injuries. In the same year, the company also entered into a partnership with Cancer Research UK to develop new cancer immunotherapies. In summary, Lineage Cell Therapeutics Inc is a company specializing in the development and marketing of cell therapies for the treatment of various diseases. The company's business model is based on the use of human embryonic stem cells and a diverse product portfolio encompassing various divisions, including neuroscience, ophthalmology, immunology, and oncology. Through strategic partnerships and acquisitions, the company aims to strengthen its position in the industry and continue its mission to develop innovative treatment options for patients in need.

What is the Lineage Cell Therapeutics dividend?

Lineage Cell Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Lineage Cell Therapeutics pay dividends?

The dividend cannot currently be calculated for Lineage Cell Therapeutics or the company does not pay out a dividend.

What is the Lineage Cell Therapeutics ISIN?

The ISIN of Lineage Cell Therapeutics is US53566P1093.

What is the Lineage Cell Therapeutics WKN?

The WKN of Lineage Cell Therapeutics is A2PP89.

What is the Lineage Cell Therapeutics ticker?

The ticker of Lineage Cell Therapeutics is LCTX.

How much dividend does Lineage Cell Therapeutics pay?

Over the past 12 months, Lineage Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lineage Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Lineage Cell Therapeutics?

The current dividend yield of Lineage Cell Therapeutics is .

When does Lineage Cell Therapeutics pay dividends?

Lineage Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lineage Cell Therapeutics?

Lineage Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Lineage Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lineage Cell Therapeutics located?

Lineage Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lineage Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lineage Cell Therapeutics from 10/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2024.

When did Lineage Cell Therapeutics pay the last dividend?

The last dividend was paid out on 10/12/2024.

What was the dividend of Lineage Cell Therapeutics in the year 2023?

In the year 2023, Lineage Cell Therapeutics distributed 0 USD as dividends.

In which currency does Lineage Cell Therapeutics pay out the dividend?

The dividends of Lineage Cell Therapeutics are distributed in USD.

All fundamentals about Lineage Cell Therapeutics

Our stock analysis for Lineage Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lineage Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.